News | June 10, 2026
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Subscribe To Our Newsletter & Stay Updated